In re EpiPen (Epinephrine Injection, USP) Marketing, Sales Practices and Antitrust Litigation
US District Court, District of Kansas
MDL No. 2785
Keller Rohrback is glad to be co-lead counsel in this significant suit about the estimating of EpiPens.
For the most recent case refreshes, including letting it be known about proposed goal and forthcoming preliminary, see this site: www.EpiPenClassAction.com
Mylan Settlement Update
Update: March 11, 2022. “We are satisfied that the Court for starters endorsed this settlement with the Mylan respondents in the EpiPen roundabout buyer case. As we said in our primer endorsement papers, we keep on accepting this settlement is an extraordinary outcome for the class.” – Lynn Sarko (Co-Lead Counsel and overseeing accomplice of Keller Rohrback). Visit EpiPenClassAction.com to find out additional.
February 28, 2022: According to Co-Lead Counsel and Managing Partner of Keller Rohrback Lynn Sarko, “The present declaration of our $264 million-dollar settlement with Mylan carries the absolute recuperation to EpiPen class individuals to $609 million. We ask customers and outsider payors who paid for EpiPens to visit EpiPenClassAction.com to get more familiar with the present settlement.”
Pfizer Settlement Update
On November 17, 2021, the Court entered a request giving last endorsement to the settlement among Plaintiffs and the Pfizer Defendants. This request and other key case records are accessible on the Settlement Administrator’s site EpiPenClassAction.com (see Case Documents tab). Requests connecting with the settlement can be coordinated to the Settlement Administrator, A.B. Information, at (877) 221-7632.